Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis
JNCI Cancer Spectrum · 2025
DOI: 10.1093/jncics/pkaf083 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Francesco Schettini und 20 weiteren Autor:innen. Beteiligte Einrichtung: Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Pyridines, Piperazines, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are the standard-of-care for hormone receptor-positive (HR+)/HER2-negative (HER2−) metastatic breast cancer (MBC). Palbociclib, the first approved CDK4/6i, significantly improved progression-free survival (PFS) in randomized controlled trials (RCTs). However, real-world (RW) outcomes may differ due to broader patient populations. This meta-analysis evaluates the applicability of pivotal RCT findings to RW settings.
Methods
We conducted a systematic review and meta-analysis of RW studies on HR+/HER2− MBC treated with palbociclib+aromatase inhibitors (AI) or fulvestrant, reporting median PFS (mPFS) and/or overall survival (mOS). Pooled mPFS/OS was estimated using the median of medians (MM) and weighted MM (WM). RW estimates were deemed comparable to RCTs if MMPFS/OS or WMPFS/OS fell within RCTs’ 95% confidence intervals (CIs). Similar criteria applied to pooled hazard ratios (HRs) of PFS/OS for palbociclib+AI vs AI in visceral/nonvisceral subgroups.
Results
Twelve RW studies were analyzed. First-line palbociclib+AI MMPFS (22.5 months, 95% CI = 19.5 to 31.8) aligned with PALOMA-1/2 pooled mPFS (23.9, 95% CI = 20.2 to 27.6). First-line palbociclib+fulvestrant MMPFS (13.5, 95% CI = 11.6 to 28.5) exceeded PALOMA-3 (11.2, 95% CI = 9.5 to 12.9). Second-line palbociclib+fulvestrant MMPFS (11.5 months, 95% CI = 6.3 to 15.3) was consistent with PALOMA-3. RW first-line mOS (51.2 months, 95% CI = 49.1 to 53.3) surpassed PALOMA-1/2 pooled mOS (45.7, 95% CI = 37.5 to 53.8). WMOS (49.1 months, 95% CI = 49.1 to 53.3) was slightly lower than RCTs (53.7, 95% CI = 37.5 to 53.8). Palbociclib+AI outperformed AI in RW visceral disease, aligning with RCTs, and showed heterogeneous but favorable benefit in nonvisceral disease.
Conclusions
RW data confirm palbociclib+endocrine therapy effectiveness, reinforcing its applicability to broader patient populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
- Department of Medical Oncology, Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.
- Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
- Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
- Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.
- Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
ORCID-Profile: Francesco Schettini, Sabrina Nucera, Giuseppe Di Grazia, Fabiola Giudici, Benedetta Conte, Carmen Criscitiello, Mario Giuliano, Matteo Lambertini, Rodrigo Sánchez-Bayona, Tomás Pascual, Grazia Arpino, Lucia Del Mastro, Paolo Vigneri, Massimo Cristofanilli, Hope S Rugo, Alessandra Gennari, Giuseppe Curigliano, Daniele Generali
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Schettini, F., Nucera, S., Di Grazia, G., Giudici, F., Strina, C., Milani, M., Tancredi, R., Conte, B., Criscitiello, C., Giuliano, M., Lambertini, M., Sánchez-Bayona, R., Pascual, T., Arpino, G., Del Mastro, L., Vigneri, P., Cristofanilli, M., Rugo, H. S., Gennari, A., …, & Generali, D. (2025). Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf083
Vancouver
Schettini F, Nucera S, Di Grazia G, Giudici F, Strina C, Milani M, et al. Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkaf083
BibTeX
@article{Schettini2025,
author = {Schettini, Francesco and Nucera, Sabrina and Di Grazia, Giuseppe and Giudici, Fabiola and Strina, Carla and Milani, Manuela and Tancredi, Richard and Conte, Benedetta and Criscitiello, Carmen and Giuliano, Mario and Lambertini, Matteo and Sánchez-Bayona, Rodrigo and Pascual, Tomás and Arpino, Grazia and Del Mastro, Lucia and Vigneri, Paolo and Cristofanilli, Massimo and Rugo, Hope S and Gennari, Alessandra and Curigliano, Giuseppe and Generali, Daniele},
title = {Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis},
journal = {JNCI Cancer Spectrum},
year = {2025},
doi = {10.1093/jncics/pkaf083}
}
EUVIMED